IL1B and deep vein thrombosis: Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) demonstrated that inhibition of IL-1β in patients with atherosclerosis can reduce the incidence of major cardiovascular events (43, 44).